Reduction in Acute Limb Ischemia With Rivaroxaban Versus Placebo in Peripheral Artery Disease After Lower Extremity Revascularization: Insights From VOYAGER PAD.
Connie N HessEike Sebastian DebusMark R NehlerSonia S AnandManesh R PatelMichael SzarekWarren H CapellJudith HsiaJoshua A BeckmanMarianne BrodmannRafael DiazPeter HabertheuerNicholas J LeeperRichard J PowellHenrik SillesenEva MuehlhoferScott D BerkowitzLloyd P HaskellRupert M BauersachsMarc P BonacaPublished in: Circulation (2021)
After LER for symptomatic PAD, ALI is frequent, particularly early after LER, and is associated with poor prognosis. Low-dose rivaroxaban plus aspirin reduces ALI after LER, including ALI events associated with the most severe outcomes. The benefit of rivaroxaban for ALI appears early, continues over time, and is consistent regardless of revascularization approach or clopidogrel use.
Keyphrases
- poor prognosis
- low dose
- venous thromboembolism
- atrial fibrillation
- percutaneous coronary intervention
- peripheral artery disease
- pulmonary embolism
- long non coding rna
- antiplatelet therapy
- coronary artery bypass grafting
- acute coronary syndrome
- high dose
- liver failure
- drug induced
- coronary artery disease
- clinical trial
- type diabetes
- randomized controlled trial
- intensive care unit
- adipose tissue
- cardiovascular events
- aortic dissection
- acute respiratory distress syndrome
- extracorporeal membrane oxygenation
- placebo controlled
- study protocol